M.E. Thase

783 total citations
21 papers, 593 citations indexed

About

M.E. Thase is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, M.E. Thase has authored 21 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 7 papers in Experimental and Cognitive Psychology and 6 papers in Psychiatry and Mental health. Recurrent topics in M.E. Thase's work include Treatment of Major Depression (11 papers), Mental Health Research Topics (6 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers). M.E. Thase is often cited by papers focused on Treatment of Major Depression (11 papers), Mental Health Research Topics (6 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (3 papers). M.E. Thase collaborates with scholars based in United States, Denmark and Canada. M.E. Thase's co-authors include Alan G. Mallinger, Jonathan M. Himmelhoch, Dianalee McKnight, David J. Kupfer, Ellen Frank, Christine Cherry, Daniel J. Buysse, Cleon Cornes, Diane L. Spangler and Anne D. Simons and has published in prestigious journals such as American Journal of Psychiatry, Clinical Infectious Diseases and Biological Psychiatry.

In The Last Decade

M.E. Thase

21 papers receiving 556 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.E. Thase United States 11 252 225 223 135 127 21 593
Charles S. Wilcox United States 16 272 1.1× 275 1.2× 320 1.4× 135 1.0× 171 1.3× 27 806
Maurizio Fava United States 12 163 0.6× 279 1.2× 295 1.3× 177 1.3× 116 0.9× 14 787
Cláudia Hara Brazil 12 140 0.6× 180 0.8× 146 0.7× 99 0.7× 59 0.5× 27 481
G Charles Belgium 14 155 0.6× 180 0.8× 184 0.8× 163 1.2× 130 1.0× 41 721
Nicholas Rosenlicht United States 11 175 0.7× 181 0.8× 166 0.7× 191 1.4× 59 0.5× 14 577
S. De Risio Italy 16 173 0.7× 137 0.6× 157 0.7× 120 0.9× 158 1.2× 26 625
Hermes Andreas Kick Germany 10 184 0.7× 146 0.6× 133 0.6× 87 0.6× 159 1.3× 27 525
Nick J. Coupland Canada 10 95 0.4× 186 0.8× 154 0.7× 116 0.9× 173 1.4× 12 580
A. P. P. van Willigenburg Netherlands 6 213 0.8× 160 0.7× 246 1.1× 128 0.9× 43 0.3× 6 531
Joseph Deltito United States 20 351 1.4× 408 1.8× 224 1.0× 100 0.7× 347 2.7× 34 962

Countries citing papers authored by M.E. Thase

Since Specialization
Citations

This map shows the geographic impact of M.E. Thase's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.E. Thase with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.E. Thase more than expected).

Fields of papers citing papers by M.E. Thase

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.E. Thase. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.E. Thase. The network helps show where M.E. Thase may publish in the future.

Co-authorship network of co-authors of M.E. Thase

This figure shows the co-authorship network connecting the top 25 collaborators of M.E. Thase. A scholar is included among the top collaborators of M.E. Thase based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.E. Thase. M.E. Thase is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ismail, Zahinoor, M.E. Thase, Catherine Weiss, et al.. (2020). P.565 A post-hoc analysis of the effect of brexpiprazole on patient engagement in patients with schizophrenia. European Neuropsychopharmacology. 40. S319–S320. 1 indexed citations
2.
Fava, M., Bryan Dirks, Richard C. Shelton, et al.. (2019). P.032 A phase-2, double-blind, placebo-controlled, sequential parallel comparison design study of efficacy and safety of adjunctive pimavanserin in major depressive disorder. European Neuropsychopharmacology. 29. S42–S43. 1 indexed citations
3.
Vittengl, Jeffrey R., et al.. (2011). Change in psychosocial functioning and depressive symptoms during acute-phase cognitive therapy for depression. Psychological Medicine. 42(2). 317–326. 39 indexed citations
4.
5.
Keller, Martin B., Bing Chun Yan, James M. Ferguson, et al.. (2006). P.2.c.019 Two-year maintenance treatment study assessing recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression. European Neuropsychopharmacology. 16. S322–S323. 1 indexed citations
6.
Detke, Michael J., Satish Iyengar, Judith Henck, et al.. (2006). Cardiovascular Effects of Duloxetine: Preclinical and Clinical Findings. 3(3). 407–408. 3 indexed citations
7.
Manber, Rachel, Christine Blasey, Bruce A. Arnow, et al.. (2005). Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. Journal of Psychiatric Research. 39(5). 481–488. 66 indexed citations
8.
Nemeroff, Charles B., A.R. Entsuah, Lauren Willard, Mark A. Demitrack, & M.E. Thase. (2003). P.1.189 Venlafaxine and SSRIs: Pooled remission analysis. European Neuropsychopharmacology. 13. S255–S255. 2 indexed citations
9.
Thase, M.E., et al.. (2003). P.1.199 Remission rates following therapy with bupropion or selective serotonin reuptake inhibitors. European Neuropsychopharmacology. 13. S259–S259. 3 indexed citations
10.
Thase, M.E., et al.. (2003). P.1.096 Remission rates in double-blind, placebo-controlled clinical trials of duloxetine with SSRI as a comparator. European Neuropsychopharmacology. 13. S215–S215. 7 indexed citations
11.
Thase, M.E., Edward S. Friedman, & Robert H. Howland. (2000). Venlafaxine and treatment-resistant depression. Depression and Anxiety. 12(S1). 55–62. 25 indexed citations
12.
Thase, M.E.. (1999). When are Psychotherapy and Pharmacotherapy Combinations the Treatment of Choice for Major Depressive Disorder?. Psychiatric Quarterly. 70(4). 333–346. 18 indexed citations
13.
Salloum, Ihsan M., et al.. (1998). Naltrexone utility in depressed alcoholics.. PubMed. 34(1). 111–5. 47 indexed citations
14.
Perlis, Michael L., et al.. (1998). 319. Do nocturnal awakenings differ in depressed subjects vs normal control subjects?. Biological Psychiatry. 43(8). S96–S96. 1 indexed citations
15.
Thase, M.E., Martin B. Keller, Alan J. Gelenberg, Robert M. A. Hirschfeld, & Alan F. Schatzberg. (1997). Double-blind crossover antidepressant study: Sertraline vs. imipramine. Biological Psychiatry. 42(1). 230S–230S. 2 indexed citations
16.
Thase, M.E., Daniel J. Buysse, Ellen Frank, et al.. (1997). Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. American Journal of Psychiatry. 154(4). 502–509. 108 indexed citations
17.
Spangler, Diane L., Anne D. Simons, Scott M. Monroe, & M.E. Thase. (1993). Evaluating the hopelessness model of depression: Diathesis-stress and symptom components.. Journal of Abnormal Psychology. 102(4). 592–600. 39 indexed citations
18.
Thase, M.E., Alan G. Mallinger, Dianalee McKnight, & Jonathan M. Himmelhoch. (1992). Treatment of imipramine-resistant recurrent depression, IV: A double- blind crossover study of tranylcypromine for anergic bipolar depression. American Journal of Psychiatry. 149(2). 195–198. 132 indexed citations
19.
Thase, M.E.. (1991). Assessment of Depression in Patients with Chronic Fatigue Syndrome. Clinical Infectious Diseases. 13(Supplement_1). S114–S118. 15 indexed citations
20.
Mallinger, Alan G., Jonathan M. Himmelhoch, M.E. Thase, David J. Edwards, & Steven Knopf. (1990). Plasma tranylcypromine: relationship to pharmacokinetic variables and clinical antidepressant actions.. PubMed. 10(3). 176–83. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles S. Wilcox Breakdown of academic impact, for papers by Maurizio Fava Breakdown of academic impact, for papers by Cláudia Hara Breakdown of academic impact, for papers by G Charles Breakdown of academic impact, for papers by Nicholas Rosenlicht Breakdown of academic impact, for papers by S. De Risio Breakdown of academic impact, for papers by Hermes Andreas Kick Breakdown of academic impact, for papers by Nick J. Coupland Breakdown of academic impact, for papers by A. P. P. van Willigenburg Breakdown of academic impact, for papers by Joseph Deltito
Rankless by CCL
2026